WuXi PharmaTech and Huawei introduce first Chinese cloud platform for individualized medicine

May 25, 2016

Under the „135“ program, WuXi and Huawei will comply with the relevant provisions of the State Food and Drug Administration (CFDA), through cooperation with third-party security life sciences cloud platform vendors, joint development for Chinese Medicine Program and precise data exchange standards and frameworks.

China Bio news release, May 25, 2016

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny